Company intelligence / Profile preview

Carlyle FRL

Lexington, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Carlyle FRL is a specialized entity associated with the development and commercialization of metabolic health technologies, specifically focusing on the Revita system. The company's primary focus is on duodenal mucosal resurfacing (DMR), a minimally invasive procedure designed to treat metabolic diseases such as type 2 diabetes and obesity by resurfacing the lining of the duodenum. This intervention aims to improve glycemic control and insulin resistance by altering the hormonal signaling in the gut. Carlyle FRL operates within the broader ecosystem of metabolic health innovation, leveraging clinical data to provide non-pharmacological alternatives for chronic metabolic conditions.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: DeviceNon-pharmacological therapy
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Carlyle FRL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carlyle FRL.

Explore the full profile